Dont have an account?Sign up here
Oliver Heald | Yesterday's sickening incident in Woolwich…
13:03Oliver Heald\'s Blog
I absolutely condemn the horrific actions which took place in Woolwich yesterday afternoon. Praise should go to the club scout leader Ingrid Loyau-Kennett for bravely attempting to defuse the situatio...
Anouchka Grose | What we can learn from Ingrid Loyau-Kennet's grace under pressure
12:55Comment is Free
Geeks! The House Magazine guide to Select Committees has been published. Downloa...
12:52Tony Grew
Geeks! The House Magazine guide to Select Committees has been published. Download it here: http://t.co/XynqJOgKBw
Ken Livingstone | The Woolwich attack will not break London - or its unity
12:52The Guardian
After 7/7 there were no reprisal attacks to give the terrorists what they wanted. London can stand strong after this murder too.
The opinion of the IMF shouldn't matter, but Osborne has ensured itdoes
12:20The Independent
Does the opinion of the International Monetary Fund matter? It shouldn’t really. Unlike Greece or Ireland, Britain is not in an official bailout programme. We’re not beholden to the Fund for cash. But...
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
PoliticsHome | Only the latest five entries on the PhiWire are visible to non-subscribers
01:05 Sign up to see last 24 hours
Only the latest five entries on the PhiWire are visible to non-subscribers, Sign up to see last 24 hours
18 April 2012
Breakthrough Breast Cancer comments on NICE's decision to open a consultation on new, draft guidance which does not recommend bevacizumab (Avastin) for the first-time treatment of metastatic breast cancer, when used in combination with the chemotherapy drug, capecitabine.
Dr Rachel Greig, Senior Policy Officer at Breakthrough Breast Cancer, said:
"We welcome new treatments for women with metastatic breast cancer as we know their options are limited and prolonging life is incredibly important to them and their families.
However, this treatment combination can cause serious side effects and there is no evidence to show how this may affect a patient's quality of life.”